Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stillen Tab. vs Patisren Tab. in Acute or Chronic Gastritis (Phase IV Non-Inferiority Study)
KCT0012025Phase 4Not yet recruiting
- Sponsor
- Richwood Trading Company
- Start
- Jun 2026
- Modality
- Gene Therapies, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Stillen and patisiran in acute gastritis and chronic gastritis (2 arms), sponsored by Richwood Trading Company. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
Stillenpatisiran
03
Conditions
acute gastritischronic gastritis
Beyond the preview
Go deeper on KCT0012025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0012025.